MYRIAD GENETICS, INC. Deferred Income Tax Liabilities, Net
MYRIAD GENETICS, INC. (MYGN) had Deferred Income Tax Liabilities, Net of $2.70 million as of 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2023-11-07
- 2023-09-30: Deferred Income Tax Liabilities, Net $2.70M.
- 2023-06-30: Deferred Income Tax Liabilities, Net $3.70M.
- 2023-03-31: Deferred Income Tax Liabilities, Net $4.10M.
- 2022-12-31: Deferred Income Tax Liabilities, Net $3.50M.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2023-09-30 | $2.70M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $3.70M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $4.10M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $3.50M 10-Q · filed 2023-11-07 |
| 2022-09-30 | $10.50M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $23.30M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $29.90M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $35.80M 10-K · filed 2023-03-01 |
| 2021-09-30 | $40.70M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $58.20M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $59.20M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $71.30M 10-K · filed 2022-02-25 |
| 2020-09-30 | $75.30M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $26.60M 10-KT · filed 2021-03-16 |
| 2019-06-30 | $82.60M 10-KT · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |